PDCD1 and melanoma: Filipski et al. (2021) [98] used the Illumina MethylationEPIC BeadChip technology to investigate methylation signatures across the genomes of 61 stage IV melanoma patients who were treated with anti-PD-1-ICI during the course of their disease, along with Illumina 450 K methylation bead chip array data from a further 396 melanoma patients (stages I–IV, skin, soft tissue, central nervous system, peripheral, non-central nervous system organs, and lymph nodes) from The Cancer Genome Atlas (TCGA).